Pulmonary Hypertension
NO LONGER ACCEPTING APPLICATIONS
Published on:
September 18, 2024
Sign-up Expiration:
Updated:
Locations:
Rock Hill, SC
Dr. Naresh Mori
The primary objective of this study is to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment. Additional safety, function and symptoms, hemodynamic, and biomarker assessments will also be performed, with key secondary endpoints assessed at baseline and after 12 and 24 weeks of treatment. Right heart catheterization (RHC) and echocardiograms will be performed at baseline and after 24 weeks of treatment.
ENDED